Search Results 581-590 of 16980 for pharmacogenetics
Mayo Clinic researcher Wei Shen, Ph.D., studies hereditary cancer predisposition syndromes and rare diseases.
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
About this study. This protocol is being conducted to determine the mechanisms responsible for insulin resistance, obesity and type 2 diabetes.
Rochester, Minn., Jacksonville, Fla., Scottsdale/Phoenix, Ariz. The primary objective of the study is to compare sacituzumab tirumotecan combined with ...
Drugs used in chemotherapy, such as gemcitabine hydrochloride, cisplatin, and nab-paclitaxel, work in different ways to stop the growth of tumor cells, either ...
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies such as trastuzumab can ...
About this study. The purpose of this study is to evaluate the dose, safety, immunogenicity and early clinical activity of GRT-C903 and GRT-R904, ...
Everolimus may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Brentuximab vedotin may interfere with the ability of ...
Learn about this common cancer, including information on prevention, symptoms, diagnosis and treatment.
Genetic Variations May Help Identify Best Candidates for Preventive Breast Cancer Drugs. ROCHESTER, Minn. — Newly discovered genetic variations may help ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
Your gift to celebrate this day advances our doctors’ lifesaving work.